Literature DB >> 23408144

Aromatase inhibitor adjuvant chemotherapy of breast cancer results in cancer therapy induced bone loss.

Renee Z Rinaldi1.   

Abstract

Aromatase Inhibitors are anti-estrogen agents that have proven efficacy for adjuvant therapy of estrogen receptor positive breast cancer primarily in post menopausal women with estrogen receptor positive breast cancer but increase the risk of cancer therapy induced bone loss (CTIBL). Recent studies have shown the potential benefit of bisphosphonate therapy to play a dual role in the management of breast cancer. These studies provide evidence that bisphosphonate therapy in conjunction with aromatase inhibitors (AI), not only decreases the risk of osteoporosis but, in addition, may improve survival from breast cancer.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23408144     DOI： 10.1007/s11914-013-0134-7

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN： 1544-1873            Impact factor:   5.096


  21 in total

1.  Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.

Authors:  H Eidtmann; R de Boer; N Bundred; A Llombart-Cussac; N Davidson; P Neven; G von Minckwitz; J Miller; N Schenk; R Coleman
Journal:  Ann Oncol       Date:  2010-05-05       Impact factor: 32.976

2.  Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.

Authors:  Adam M Brufsky; W Graydon Harker; J Thaddeus Beck; Linda Bosserman; Charles Vogel; Christopher Seidler; Lixian Jin; Ghulam Warsi; Eliza Argonza-Aviles; John Hohneker; Solveig G Ericson; Edith A Perez
Journal:  Cancer       Date:  2011-10-10       Impact factor: 6.860

3.  Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

Authors:  Michael Gnant; Brigitte Mlineritsch; Herbert Stoeger; Gero Luschin-Ebengreuth; Dietmar Heck; Christian Menzel; Raimund Jakesz; Michael Seifert; Michael Hubalek; Gunda Pristauz; Thomas Bauernhofer; Holger Eidtmann; Wolfgang Eiermann; Guenther Steger; Werner Kwasny; Peter Dubsky; Gerhard Hochreiner; Ernst-Pius Forsthuber; Christian Fesl; Richard Greil
Journal:  Lancet Oncol       Date:  2011-06-05       Impact factor: 41.316

Review 4.  Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.

Authors:  Eitan Amir; Bostjan Seruga; Saroj Niraula; Lindsay Carlsson; Alberto Ocaña
Journal:  J Natl Cancer Inst       Date:  2011-07-09       Impact factor: 13.506

5.  Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.

Authors:  Per E Lønning; Jürgen Geisler; Lars E Krag; Bjørn Erikstein; Yngve Bremnes; Anne I Hagen; Ellen Schlichting; Ernst A Lien; Erik S Ofjord; Jolanda Paolini; Anna Polli; Giorgio Massimini
Journal:  J Clin Oncol       Date:  2005-06-27       Impact factor: 44.544

6.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Authors:  Michael Gnant; Brigitte Mlineritsch; Walter Schippinger; Gero Luschin-Ebengreuth; Sabine Pöstlberger; Christian Menzel; Raimund Jakesz; Michael Seifert; Michael Hubalek; Vesna Bjelic-Radisic; Hellmut Samonigg; Christoph Tausch; Holger Eidtmann; Günther Steger; Werner Kwasny; Peter Dubsky; Michael Fridrik; Florian Fitzal; Michael Stierer; Ernst Rücklinger; Richard Greil; C Marth
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

7.  Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome.

Authors:  Leilani Morales; Steven Pans; Kilian Verschueren; Ben Van Calster; Robert Paridaens; Rene Westhovens; Dirk Timmerman; Luc De Smet; Ignace Vergote; Marie-Rose Christiaens; Patrick Neven
Journal:  J Clin Oncol       Date:  2008-05-12       Impact factor: 44.544

8.  Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.

Authors:  David M Reid; Julie Doughty; Richard Eastell; Steven D Heys; Anthony Howell; Eugene V McCloskey; Trevor Powles; Peter Selby; Robert E Coleman
Journal:  Cancer Treat Rev       Date:  2008-06-02       Impact factor: 12.111

9.  Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.

Authors:  Georgiana K Ellis; Henry G Bone; Rowan Chlebowski; Devchand Paul; Silvana Spadafora; Judy Smith; Michelle Fan; Susie Jun
Journal:  J Clin Oncol       Date:  2008-08-25       Impact factor: 44.544

10.  Breast-cancer adjuvant therapy with zoledronic acid.

Authors:  Robert E Coleman; Helen Marshall; David Cameron; David Dodwell; Roger Burkinshaw; Maccon Keane; Miguel Gil; Stephen J Houston; Robert J Grieve; Peter J Barrett-Lee; Diana Ritchie; Julia Pugh; Claire Gaunt; Una Rea; Jennifer Peterson; Claire Davies; Victoria Hiley; Walter Gregory; Richard Bell
Journal:  N Engl J Med       Date:  2011-09-25       Impact factor: 91.245
View more
  4 in total

1.  CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy.

Authors:  Federica Mazzuca; Andrea Botticelli; Eva Mazzotti; Marco La Torre; Marina Borro; Luca Marchetti; Chiara Maddalena; Giovanna Gentile; Maurizio Simmaco; Paolo Marchetti
Journal:  Eurasian J Med       Date:  2015-07-07

2.  Use of MR-based trabecular bone microstructure analysis at the distal radius for osteoporosis diagnostics: a study in post-menopausal women with breast cancer and treated with aromatase inhibitor.

Authors:  Thomas Baum; Dimitrios C Karampinos; Vanadin Seifert-Klauss; Tsvetelina D Pencheva; Pia M Jungmann; Ernst J Rummeny; Dirk Müller; Jan S Bauer
Journal:  Clin Cases Miner Bone Metab       Date:  2016-05-11

3.  Low Bone Mass Secondary to Antipsychotic Medications.

Authors:  Abdallah S Al-Omran; Mahdi S Abu-Madini; Mir Sadat-Ali; Moaad H Alfaraidy; Waleed K Shihada
Journal:  Saudi J Med Med Sci       Date:  2016-08-11

4.  Osteoporosis, fracture and survival: Application of machine learning in breast cancer prediction models.

Authors:  Lichen Ji; Wei Zhang; Xugang Zhong; Tingxiao Zhao; Xixi Sun; Senbo Zhu; Yu Tong; Junchao Luo; Youjia Xu; Di Yang; Yao Kang; Jin Wang; Qing Bi
Journal:  Front Oncol       Date:  2022-08-12       Impact factor: 5.738
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.